Cardiex completes $3.25m raise to scale new Pulse biometric monitor

Cardiex has announced a $3.25m placement to scale product rollouts and drive growth in its clinical trials business in 2025
FDA-cleared Pulse medical device has attracted 20,000+ waitlist members
Pre-order sales already underway in the US

Special Report: Australian medtech Cardiex is gearing up for a pivotal 2025, announcing a $3.25 million placement to accelerate the rollout of its flagship cardiovascular health products.

Jointly managed by Blackpeak Capital and Stralis Capital Partners, the placement is priced at 9c per share and includes a one-for-one free attaching option exercisable at 20c and expiring in November 2025.

Cardiex’s (ASX:CDX) share price has lifted 65% over the past three months, reflecting investor confidence in the company’s performance and outlook.

The placement will enable Cardiex to execute on its strategic and revenue plan for 2025, which includes launching the company’s new medical device the CONNEQT Pulse at scale and expanding its clinical trials business.

Following a successful waitlist campaign with over 20,000 sign-ups, manufacturing of the first 8000 units of the Pulse is well underway, and initial shipments have begun to the US. A full-scale market launch is slated for January 2025.

This article was developed in collaboration with Cardiex, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.